Posts tagged Mr. Deepak
Wainwright starts Mirna Therapeutics at buy

H.C. Wainwright initiated coverage of Mirna Therapeutics (NASDAQ:MIRN) with a ‘buy” rating and $6 price target, saying the company’s promising microRNA technology “could be a gift to long-term investors.” The stock was quoted at $2.50 on Monday afternoon.

“We believe the current Mirna share price offers an attractive entry point for long-term investors, as the stock is trading well below the $73-million June cash position,” writes analyst Shaunak Deepak.

Read More